These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34225753)

  • 41. Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era.
    Giancane G; Muratore V; Marzetti V; Quilis N; Benavente BS; Bagnasco F; Alongi A; Civino A; Quartulli L; Consolaro A; Ravelli A
    Arthritis Res Ther; 2019 Jul; 21(1):168. PubMed ID: 31287015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Factors and glucocorticoid usage affecting the prognosis of systemic juvenile idiopathic arthritis.
    Paç Kısaarslan A; Özdemir Çiçek S; Şahin N; Başol M; Doğantan Ş; Taşkın SN; Poyrazoğlu MH
    Pediatr Int; 2021 Dec; 63(12):1424-1432. PubMed ID: 33760311
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
    Lainka E; Baehr M; Raszka B; Haas JP; Hügle B; Fischer N; Foell D; Hinze C; Weissbarth-Riedel E; Kallinich T; Horneff G; Windschall D; Lilienthal E; Niehues T; Neudorf U; Berendes R; Küster RM; Oommen PT; Rietschel C; Lutz T; Weller-Heinemann F; Tenbrock K; Heubner GL; Klotsche J; Wittkowski H
    Pediatr Rheumatol Online J; 2021 Mar; 19(1):38. PubMed ID: 33752669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Canakinumab for the treatment of systemic juvenile idiopathic arthritis.
    Grom AA
    Expert Rev Clin Immunol; 2014 Nov; 10(11):1427-35. PubMed ID: 25269376
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Systemic Juvenile Idiopathic Arthritis-Associated Lung Disease: Characterization and Risk Factors.
    Schulert GS; Yasin S; Carey B; Chalk C; Do T; Schapiro AH; Husami A; Watts A; Brunner HI; Huggins J; Mellins ED; Morgan EM; Ting T; Trapnell BC; Wikenheiser-Brokamp KA; Towe C; Grom AA
    Arthritis Rheumatol; 2019 Nov; 71(11):1943-1954. PubMed ID: 31379071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries.
    Swart J; Giancane G; Horneff G; Magnusson B; Hofer M; Alexeeva Е; Panaviene V; Bader-Meunier B; Anton J; Nielsen S; De Benedetti F; Kamphuis S; Staņēviča V; Tracahana M; Ailioaie LM; Tsitsami E; Klein A; Minden K; Foeldvari I; Haas JP; Klotsche J; Horne AC; Consolaro A; Bovis F; Bagnasco F; Pistorio A; Martini A; Wulffraat N; Ruperto N;
    Arthritis Res Ther; 2018 Dec; 20(1):285. PubMed ID: 30587248
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Growth and body mass index in a cohort of patients with juvenile idiopathic arthritis: effects of second line treatments.
    Marino A; Stagi S; Simonini G; Carli N; Caparello MC; Giani T; Pagnini I; De Masi S; Cimaz R
    Clin Exp Rheumatol; 2018; 36(5):929-933. PubMed ID: 30148444
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Systemic juvenile idiopathic arthritis versus adult-onset Still´s disease: the pertinence of changing the current classification criteria.
    Silva JR; Brito I
    Acta Reumatol Port; 2020; 45(2):150-151. PubMed ID: 32895357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. JAK inhibitors in systemic juvenile idiopathic arthritis.
    He T; Xia Y; Luo Y; Yang J
    Front Pediatr; 2023; 11():1134312. PubMed ID: 37152309
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognosis, complications and treatment response in systemic juvenile idiopathic arthritis patients: A single-center experience.
    Barut K; Adrovic A; Sahin S; Tarcin G; Tahaoglu G; Koker O; Yildiz M; Kasapcopur O
    Int J Rheum Dis; 2019 Sep; 22(9):1661-1669. PubMed ID: 31273940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparisons of the outcomes between early and late tocilizumab treatment in systemic juvenile idiopathic arthritis.
    Pacharapakornpong T; Vallibhakara SA; Lerkvaleekul B; Vilaiyuk S
    Rheumatol Int; 2017 Feb; 37(2):251-255. PubMed ID: 27798725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Access to pediatric rheumatology care for Juvenile Idiopathic Arthritis in the United Arab Emirates.
    Khawaja K; Al-Maini M
    Pediatr Rheumatol Online J; 2017 May; 15(1):41. PubMed ID: 28511684
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Treatment to Target Using Recombinant Interleukin-1 Receptor Antagonist as First-Line Monotherapy in New-Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five-Year Follow-Up Study.
    Ter Haar NM; van Dijkhuizen EHP; Swart JF; van Royen-Kerkhof A; El Idrissi A; Leek AP; de Jager W; de Groot MCH; Haitjema S; Holzinger D; Foell D; van Loosdregt J; Wulffraat NM; de Roock S; Vastert SJ
    Arthritis Rheumatol; 2019 Jul; 71(7):1163-1173. PubMed ID: 30848528
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The frequency of infections in patients with juvenile idiopathic arthritis on biologic agents: 1-year prospective study.
    Aygun D; Sahin S; Adrovic A; Barut K; Cokugras H; Camcıoglu Y; Kasapcopur O
    Clin Rheumatol; 2019 Apr; 38(4):1025-1030. PubMed ID: 30448935
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of Biologic Therapy on Clinical and Laboratory Features of Macrophage Activation Syndrome Associated With Systemic Juvenile Idiopathic Arthritis.
    Schulert GS; Minoia F; Bohnsack J; Cron RQ; Hashad S; KonÉ-Paut I; Kostik M; Lovell D; Maritsi D; Nigrovic PA; Pal P; Ravelli A; Shimizu M; Stanevicha V; Vastert S; Woerner A; de Benedetti F; Grom AA
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):409-419. PubMed ID: 28499329
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Joint lavage for treating recurrent knee involvement in patients with juvenile idiopathic arthritis.
    Sornay-Soares C; Job-Deslandre C; Kahan A
    Joint Bone Spine; 2004 Jul; 71(4):296-9. PubMed ID: 15288854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of Effectiveness of Anakinra in Systemic Juvenile Idiopathic Arthritis.
    Saccomanno B; Tibaldi J; Minoia F; Bagnasco F; Pistorio A; Guariento A; Caorsi R; Consolaro A; Gattorno M; Ravelli A
    J Rheumatol; 2019 Apr; 46(4):416-421. PubMed ID: 30647180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
    JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis.
    Kostik MM; Dubko MF; Masalova VV; Snegireva LS; Kornishina TL; Chikova IA; Isupova EA; Kuchinskaya EM; Glebova NI; Buchinskaya NV; Kalashnikova OV; Chasnyk VG
    Pediatr Rheumatol Online J; 2015; 13():4. PubMed ID: 25685108
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Glucocorticoids in juvenile idiopathic arthritis.
    Schiappapietra B; Varnier G; Rosina S; Consolaro A; Martini A; Ravelli A
    Neuroimmunomodulation; 2015; 22(1-2):112-8. PubMed ID: 25227183
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.